Modernizing Alzheimer's Diagnosis and Access Policy to Capitalize on New Treatment Breakthroughs
Source: "I watched my grandmother vanish into dementia. New science offers families hope | Fox News." September 6, 2026. www.foxnews.com
The Gist
The author, whose grandmother suffered from dementia for a decade, argues that now that we finally have real Alzheimer's treatments and early-detection blood tests, the U.S. needs to fix the slow, inconsistent diagnosis system so patients can actually get these treatments in time. She's pushing for standardized cognitive testing at doctor visits and for Congress to pass a law letting Medicare pay for the new diagnostic tests.
Conclusion
The U.S. healthcare system and Congress must urgently reform diagnostic and access policies for Alzheimer's disease to ensure patients can benefit from newly available treatments before it's too late.
Premises
- New scientific breakthroughs have produced the first treatments shown to slow cognitive decline in early-stage Alzheimer's disease, along with blood tests that can detect biological signs years before symptoms appear.
- Americans currently wait an average of three and a half years for a dementia diagnosis, by which time significant cognitive decline may have already occurred.
- Early intervention is critical to treatment effectiveness, meaning delayed diagnosis limits patients' ability to benefit from available advances.
- Cognitive assessments during Medicare wellness visits currently vary widely across practices, allowing early signs of dementia to be missed.
- Standardizing cognitive assessment tools during Medicare wellness visits would help catch decline earlier and more consistently.
- Passing the ASAP Act would allow Medicare to cover FDA-approved diagnostic tests, removing a financial/access barrier to timely diagnosis confirmation.
- The author's personal experience watching her grandmother decline over a decade without access to disease-modifying treatments illustrates the human cost of the historical research and access gap.
Assumptions
- Earlier diagnosis will actually lead to meaningfully better outcomes for most patients, not just a longer period of awareness of decline.
- Standardized cognitive assessments can be implemented without excessive cost, administrative burden, or false positives.
- Medicare coverage expansion (via the ASAP Act) is the primary or a major barrier to diagnostic test access, rather than other systemic issues (e.g., specialist shortages, testing infrastructure).
- The current treatments' benefits (slowing decline) are substantial enough to justify the policy and resource investment being advocated for.
- Policy and access reforms, rather than continued need for more basic research, are now the primary bottleneck to improving patient outcomes.